Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.

Saskia Lisa Verhaart,Carla M.L. van Herpen,Sjoukje F. Oosting,Astrid A.M. van der Veldt,Susanne Osanto,Maureen J. Aarts

Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.

2018

Saskia Lisa Verhaart
Carla M.L. van Herpen
Sjoukje F. Oosting
Astrid A.M. van der Veldt
Susanne Osanto
Maureen J. Aarts

4572Background: Although nivolumab, a programmed death 1 inhibitor, has been approved as a second line treatment for advanced renal-cell carcinoma (RCC) in Europe since 2016, its real-world experie...

Keywords:

Nivolumab
Pathology
Biomarker (medicine)
Renal cell carcinoma
Medicine
Oncology
programmed death 1
Internal medicine
Carcinoma
second line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations